#CircularRNA #ChemoResistance

Circ76691 (1 of 6 cirRNAs⏫in #Oxaliplatin resistance #ColoRectalCancer in vitro, also⏫in vivo (N=11)) acts as a miR-589-3p sponge to relieve FGF9➡️⏬CRC apoptosis

Hi circ76691➡️⏬#DiseaseFreeSurvival (TCGA CRC)

#NoncodingRNARes 2025
www.sciencedirect.com/science/arti...

PAK1 drives #CRC progression by enhancing the mRNA stability of oncogenic factors, while its inhibition synergizes with #Oxaliplatin, suppressing tumor growth, highlighting it as a potential therapeutic strategy.

#OpenAccess: doi.org/10.1016/j.ge...

The impact of albumin conjugation on the cytotoxic properties of cisplatin, oxaliplatin and auranofin in cancer cells The role of human serum albumin (HSA) in the delivery of anticancer metallodrugs remains unclear and requires further investigation. To this end, bioconjugates of HSA with the metallodrugs cisplatin (...

#OpenAccess article by Tiziano Marzo 𝘦𝘵 𝘢𝘭.
#UniversityofFlorence

𝐓𝐡𝐞 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐚𝐥𝐛𝐮𝐦𝐢𝐧 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐞 𝐜𝐲𝐭𝐨𝐭𝐨𝐱𝐢𝐜 𝐩𝐫𝐨𝐩𝐞𝐫𝐭𝐢𝐞𝐬 𝐨𝐟 𝐜𝐢𝐬𝐩𝐥𝐚𝐭𝐢𝐧, 𝐨𝐱𝐚𝐥𝐢𝐩𝐥𝐚𝐭𝐢𝐧 𝐚𝐧𝐝 𝐚𝐮𝐫𝐚𝐧𝐨𝐟𝐢𝐧 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐞𝐥𝐥𝐬

#HSA #metallodrugs
#cisplatin #oxaliplatin #auranofin

🔗 doi.org/10.1039/D5QI01487E

Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer

➡️ buff.ly/SZQZJaL

#HDAC #Oxaliplatin #CRCSM

Redirecting

Proud to see this story come to life after years of work!

If you’re interested in how mutant p53 rewires mitochondrial metabolism to shape tumor adaptation and chemoresistance, take a look 👇

doi.org/10.1016/j.bb...

#p53 #Mitochondria #ColorectalCancer #Oxaliplatin #Metabolism #CancerResearch

New Korean Study Reveals 70 as Key Age for Chemotherapy Benefits in Colorectal Cancer A recent study from Korea University highlights that oxaliplatin-based chemotherapy primarily benefits colorectal cancer patients aged 70 and younger, sparing older patients from harmful side effects.

New Korean Study Reveals 70 as Key Age for Chemotherapy Benefits in Colorectal Cancer #South_Korea #Seoul #Korea_University #Colorectal_Cancer #Oxaliplatin

Targeting PAK1 suppresses tumor progression by promoting mRNA decay of oncogenic factors and enhancing chemotherapeutic efficacy in colorectal cancer

This study unveils the novel function of P21-activated kinase 1 (#PAK1) in #ColorectalCancer (CRC) progression and highlights the potential of targeting PAK1 as a therapeutic strategy, particularly in combination with #oxaliplatin. #medsky

#OpenAccess: www.sciencedirect.com/science/arti...

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma under... Consistent with the initial analysis of 3-year disease-free survival, the extended 5-year overall survival analysis from the RESOLVE trial confirmed the survival advantage of perioperative-SOX and adj...

NEW – final results from RESOLVE:

Perioperative or postoperative #adjuvant #oxaliplatin with S1 vs adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma

#gastriccancer #gicsm

www.thelancet.com/journals/lan...